• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·TCNNF
Share

Trulieve Cannabis Corp. Stocks

$ 8.45Last Updated 06.08.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 1.62B

$ 8.45
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

19.12.2025 08:30

Despite Trump executive order, pot stocks dip as traders take profit

17.12.2025 18:35

Cannabis stocks rally as Trump 'very strongly' considering reclassifying marijuana

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'cheap' on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of TCNNF is 19.1 and suggests 126% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.08.2026 09:00

Morgan Stanley expects SpaceX's stock to rise by more than 100%. What does Cursor have to do with this?

12.08.2026 08:00

"Chipflation" isn't going anywhere. Which stocks will benefit from the memory shortage?

12.08.2026 04:01

CoreWeave's stock rose 14%. The report confirmed strong demand for cloud computing.

12.08.2026 01:13

"The Currency of the Future": The U.S. Plans to Launch the First AI Computing Power Futures

11.08.2026 23:45

"This Is a Warning of a Bear Market": Researchers Signal the End of the Rally

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026